Olaparib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HR+/HER2- Metastatic Breast Cancer (label: Deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), HER2-negative metastatic...), Metastatic Castration-Resistant Prostate Cancer, Ovarian Cancer, Breast Cancer, Prostate Cancer, Pancreatic Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (7)
US
  • Adjuvant Treatment of Germline BRCA -mutated HER2-negative High Risk Early Breast Cancer Lynparza is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious gBRCA m human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [ see Dosage and Administration (2.1) ].
  • Germline BRCA -mutated HER2-negative Metastatic Breast Cancer Lynparza is indicated for the treatment of adult patients with deleterious or suspected deleterious gBRCA m, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting. Patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
  • First-Line Maintenance Treatment of Germline BRCA -mutated Metastatic Pancreatic Adenocarcinoma Lynparza is indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCA m metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Select patients for therapy based on an FDA-approved companion diagnostic for Lynparza [see Dosage and Administration (2.1) ] .
    Outside this platform's coverage
Product first approved 2017FDA label
EU
  • Monotherapy for adults with germline BRCA1/2 mutations who have HER2-negative locally advanced or metastatic breast cancerastrazeneca.com
  • Ovarian cancer Lynparza is indicated as monotherapy for the: maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy. maintenance treatment of adult patients with platinum sensitive relapsed high grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum based chemotherapy. Lynparza...
    EMA
Product first approved 2014
JP
  • Maintenance treament of recurrent ovarian cancer in patients who are in a complete or partial response to platinum-based chemotherapy
Product first approved 2018PMDA
CA
  • Breast Cancer LYNPARZA (olaparib) is indicated for the adjuvant treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm), human epidermal growth factor receptor 2 (HER2)-negative high risk early breast cancer who have been treated with neoadjuvant or adjuvant chemotherapy. Patients must have confirmation of a germline BRCA mutation before LYNPARZA treatment is initiated (see 14 Clinical Trials, OlympiA). LYNPARZA is indicated as monotherapy for the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated...
Product first approved 2016Health Canada

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (39)
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
NCT06966700 · Merck Sharp & Dohme LLC
2025-06-30 – 2034-12-29 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms
What this study did
NCT02810743 · The Netherlands Cancer Institute
2017-01-25 – 2033-12-01 · Breast Cancer
What this study did
NCT04421963 · AstraZeneca
2020-08-04 – 2027-04-06 · Ovarian Cancer, Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT05171816 · AstraZeneca
2021-06-24 – 2027-02-05 · Metastatic Castration-resistant Prostate Cancer
What this study did
Ovarian Cancer
NCT06580314 · NRG Oncology
2025-03-12 – 2034-12-31 · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Carcinoma, Ovarian Carcinosarcoma, Ovarian High Grade Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma
What this study did
NCT06915025 · Imunon
2025-07-09 – 2032-10-31 · Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma
What this study did
NCT05255471 · National Cancer Institute, Naples
2022-01-21 – 2028-01-21 · Ovarian Cancer
What this study did
NCT04884360 · AstraZeneca
2021-05-31 – 2027-07-27 · Ovarian Cancer
What this study did
NCT03737643 · AstraZeneca
2019-01-04 – 2026-12-23 · Advanced Ovarian Cancer
What this study did
NCT04729387 · Novartis Pharmaceuticals
2021-07-22 – 2026-01-19 · Ovarian Cancer
What this study did
NCT03534453 · AstraZeneca
2018-05-29 – 2025-01-27 · Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive
What this study did
NCT03402841 · AstraZeneca
2018-01-30 – 2022-03-10 · Non-Germline BRCA Mutated Ovarian Cancer
What this study did
NCT03106987 · AstraZeneca
2017-06-08 – 2022-02-17 · Epithelial Ovarian Cancer
What this study did
Pancreatic Cancer
Other / comorbidity
NCT03486873 · Merck Sharp & Dohme LLC
2018-08-21 – 2043-08-04 · Solid Tumors, Hematologic Malignancies
What this study did
NCT06712472 · Gustave Roussy, Cancer Campus, Grand Paris
2024-06-26 – 2031-12 · Endometrial Cancer, p53abn
What this study did
NCT04380636 · Merck Sharp & Dohme LLC
2020-07-06 – 2029-07-06 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung
What this study did
NCT04269200 · AstraZeneca
2020-05-05 – 2027-04-01 · Endometrial Neoplasms
What this study did
NCT02446600 · National Cancer Institute (NCI)
2016-03-28 – 2027-03-04 · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Tumor, Ovarian Seromucinous Carcinoma, Ovarian Serous Tumor, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
NCT03976362 · Merck Sharp & Dohme LLC
2019-06-28 – 2026-01-30 · Carcinoma, Squamous Cell, Non-small-cell Lung
What this study did
NCT03976323 · Merck Sharp & Dohme LLC
2019-06-28 – 2026-01-30 · Carcinoma, Nonsquamous Non-small-cell Lung
What this study did
NCT03784014 · Institut National de la Santé Et de la Recherche Médicale, France
2019-10-19 – 2026-01-20 · Soft Tissue Sarcoma
What this study did
NCT01924533 · AstraZeneca
2013-09-03 – 2023-03-27 · Gastric Cancer
What this study did
Phase 2/3 (4)
Breast Cancer
NCT03150576 · Cambridge University Hospitals NHS Foundation Trust
2016-05 – 2034-06 · Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT07641855 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-09 – 2028-12 · Castration-resistant Prostate Cancer
What this study did
Ovarian Cancer
NCT02502266 · National Cancer Institute (NCI)
2016-05-03 – 2027-03-04 · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Transitional Cell Carcinoma, Ovarian Undifferentiated Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
What this study did
Other / comorbidity
NCT05432791 · National Cancer Institute (NCI)
2023-03-30 – 2027-01-30 · Locally Advanced Uterine Corpus Leiomyosarcoma, Metastatic Uterine Corpus Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IV Uterine Corpus Leiomyosarcoma AJCC v8, Unresectable Uterine Corpus Leiomyosarcoma
What this study did
Phase 2 (213)
Breast Cancer
NCT01042379 · QuantumLeap Healthcare Collaborative
2010-03-01 – 2031-12 · Breast Neoplasms, Breast Cancer, Breast Tumors, Angiosarcoma, TNBC - Triple-Negative Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05522491 · Hebei Medical University Fourth Hospital
2026-09-01 – 2031-09-01 · Solid Tumor
What this study did
NCT06829199 · Merck Sharp & Dohme LLC
2025-03-26 – 2031-03-18 · Early Triple Negative Breast Cancer
What this study did
NCT05332561 · German Cancer Research Center
2023-06-29 – 2030-12 · Early-stage Breast Cancer
What this study did
NCT05209529 · European Organisation for Research and Treatment of Cancer - EORTC
2024-02-01 – 2030-07-18 · TNBC - Triple-Negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
What this study did
NCT06245889 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2024-05-01 – 2030-06 · Triple Negative Breast Cancer
What this study did
NCT07005583 · Tianjin Medical University Cancer Institute and Hospital
2025-06-30 – 2030-05-20 · Triple-Negative Breast Cancer (TNBC)
What this study did
NCT05485766 · Okayama University
2024-07-16 – 2028-09-30 · Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms, Breast Cancer, BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, BRCA-Associated Breast Carcinoma
What this study did
NCT05128734 · AHS Cancer Control Alberta
2026-04-01 – 2028-07-01 · Breast Cancer Triple Negative
What this study did
NCT02849496 · National Cancer Institute (NCI)
2017-03-30 – 2027-08-26 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Metastatic Breast Carcinoma
What this study did
NCT03330847 · AstraZeneca
2018-03-07 – 2026-10-09 · Metastatic Triple Negative Breast Cancer
What this study did
NCT05498155 · AstraZeneca
2022-11-07 – 2025-09-16 · Breast Cancer
What this study did
NCT05174832 · Fudan University
2022-09-07 – 2025-03-01 · Triple Negative Breast Cancer
What this study did
NCT03801369 · Gordon Mills, MD, PhD
2018-12-12 – 2024-12-23 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma
What this study did
NCT03167619 · Duke University
2018-10-04 – 2022-06-30 · Triple Negative Breast Cancer
What this study did
NCT02789332 · GBG Forschungs GmbH
2016-09 – 2020-02 · Breast Cancer, Triple Negative Breast Neoplasms, HRpos Breast Neoplasms, BRCA 1 /2 and / or HRD
What this study did
NCT02681562 · Istituti Ospitalieri di Cremona
2016-01 – 2018-01 · Breast Cancer, Triple Negative Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05564377 · National Cancer Institute (NCI)
2023-04-07 – 2030-07-01 · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Locally Advanced Malignant Solid Neoplasm, Malignant Female Reproductive System Neoplasm, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Unresectable HER2-Negative Breast Carcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT02624973 · Haukeland University Hospital
2016-04-15 – 2030-06 · Breast Cancer
What this study did
NCT07113964 · The First Affiliated Hospital with Nanjing Medical University
2025-08-30 – 2029-03-30 · Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency
What this study did
NCT06201234 · GBG Forschungs GmbH
2024-12-13 – 2028-12-31 · Hormone Receptor Positive HER-2 Negative Breast Cancer, Advanced or Metastatic Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
What this study did
NCT04090567 · M.D. Anderson Cancer Center
2020-07-28 – 2027-12-31 · Advanced Breast Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Germline BRCA1 Gene Mutation, Germline BRCA2 Gene Mutation, HER2/Neu Negative, Metastatic Breast Carcinoma, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8
What this study did
NCT04053322 · UNICANCER
2019-08-26 – 2027-08 · ER-positive and HER2-negative Metastatic or Locally Advanced Breast Cancer, a Germline or Somatic BRCA Mutation, or a Deleterious Alteration of Other Genes Involved in Homologous Recombination Repair (HRR) or in MSI Status
What this study did
NCT03598257 · National Cancer Institute (NCI)
2019-01-18 – 2027-06-01 · Breast Inflammatory Carcinoma
What this study did
NCT04683679 · Memorial Sloan Kettering Cancer Center
2021-04-21 – 2027-01 · Triple Negative Breast Cancer, TNBC - Triple-Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer
What this study did
NCT05203445 · Memorial Sloan Kettering Cancer Center
2022-01-31 – 2027-01 · Breast Cancer
What this study did
NCT03344965 · Beth Israel Deaconess Medical Center
2018-04-01 – 2026-06-30 · Metastatic Breast Cancer, Invasive Breast Cancer, Somatic Mutation Breast Cancer (BRCA1), Somatic Mutation Breast Cancer (BRCA2), CHEK2 Gene Mutation, ATM Gene Mutation, PALB2 Gene Mutation, RAD51 Gene Mutation, BRIP1 Gene Mutation, NBN Gene Mutation
What this study did
NCT05629429 · National Taiwan University Hospital
2023-02-07 – 2025-12-31 · Metastatic Breast Cancer
What this study did
NCT05536128 · Seoul National University Hospital
2022-12-31 – 2025-12-31 · Advanced Breast Cancer
What this study did
NCT02299999 · UNICANCER
2014-04-07 – 2025-12 · Metastatic Breast Cancer
What this study did
NCT03025035 · Yuan Yuan
2017-09-10 – 2025-11-21 · Breast Cancer
What this study did
NCT05340413 · SOLTI Breast Cancer Research Group
2022-03-25 – 2025-02-03 · HER2-negative Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer
What this study did
NCT03182634 · Institute of Cancer Research, United Kingdom
2016-12-15 – 2023-11 · Advanced Breast Cancer
What this study did
NCT00494234 · AstraZeneca
2007-06-15 – 2022-12-21 · Breast Neoplasms
What this study did
NCT03205761 · Spanish Breast Cancer Research Group
2017-10-23 – 2022-12-15 · Advanced Breast Cancer
What this study did
NCT03931551 · MedSIR
2019-04-30 – 2022-03-02 · Advanced Breast Cancer
What this study did
NCT03367689 · MedSIR
2018-04-17 – 2021-12-31 · Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT03682289 · Rahul Aggarwal
2019-01-17 – 2028-03-31 · Clear Cell Renal Cell Carcinoma, Locally Advanced Pancreatic Cancer, Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Renal Cell Carcinoma, Metastatic Urothelial Carcinoma, Metastatic Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Stage IV Pancreatic Cancer, Stage IV Renal Cell Cancer, Endometrial Cancer, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT06909825 · Fusion Pharmaceuticals Inc.
2025-02-26 – 2027-05 · Metastatic Castration-resistant Prostate Cancer
What this study did
NCT03012321 · Northwestern University
2017-01-12 – 2027-01-16 · Prostate Cancer Metastatic Castration-Resistant, Abnormal DNA Repair, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer
What this study did
NCT05005728 · Xencor, Inc.
2021-10-22 – 2025-06-10 · Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT05262608 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2021-12-07 – 2024-04-26 · Prostate Cancer, Prostate Carcinoma, Metastatic Castration-resistant Prostate Cancer
What this study did
NCT01972217 · AstraZeneca
2014-04-01 – 2023-08-24 · Metastatic Castration-resistant Prostate Cancer
What this study did
Ovarian Cancer
NCT07647653 · Shandong University
2026-06-30 – 2031-02-28 · Ovarian Cancer
What this study did
NCT04742075 · Nordic Society of Gynaecological Oncology - Clinical Trials Unit
2021-12-15 – 2030-12-31 · Ovarian Cancer
What this study did
Phase 1/2 (40)
Breast Cancer
NCT03594396 · Seoul National University Hospital
2018-06-29 – 2026-12-31 · Breast Neoplasms
What this study did
NCT05933265 · Lantern Pharma Inc.
2023-06-09 – 2026-07-28 · Advanced Solid Tumor, Metastatic Solid Tumor, GBM, TNBC - Triple-Negative Breast Cancer, NSCLC, Pancreatic Adenocarcinoma, DDR Gene Mutation
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06298084 · Gustave Roussy, Cancer Campus, Grand Paris
2024-03-21 – 2029-06 · Breast Cancer Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Low Breast Carcinoma, Advanced Breast Cancer
What this study did
NCT04711824 · Colette Shen
2022-03-09 – 2026-11 · Breast Cancer, Brain Metastases, Adult
What this study did
NCT06065059 · Tango Therapeutics, Inc.
2023-12-08 – 2024-05-22 · Breast Cancer, Ovarian Cancer, Pancreas Cancer, Prostate Cancer, BRCA1 Mutation, BRCA-Mutated Ovarian Carcinoma, BRCA-Associated Breast Carcinoma, HRD Positive Advanced Ovarian Cancer
What this study did
NCT02684318 · Poveda, Andrés, M.D.
2015-07 – 2019-10 · Advanced Cancer, Ovarian Cancer, Endometrial Cancer, Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT06353386 · Merck Sharp & Dohme LLC
2024-05-20 – 2029-01-15 · Prostatic Neoplasms, Castration-Resistant
What this study did
NCT02861573 · Merck Sharp & Dohme LLC
2016-11-17 – 2028-07-24 · Metastatic Castration-Resistant Prostate Cancer
What this study did
NCT03568656 · CellCentric Ltd.
2018-07-23 – 2025-07-06 · Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
What this study did
NCT05700669 · Valerio Therapeutics
2023-02-20 – 2023-10-31 · Metastatic Castration-resistant Prostate Cancer, Recurrent Epithelial Ovarian Cancer, Breast Cancer
What this study did
NCT04556617 · Opna Bio LLC
2020-09-21 – 2022-05-24 · Metastatic Castration-resistant Prostate Cancer
What this study did
Ovarian Cancer
NCT07460180 · The Netherlands Cancer Institute
2025-05-01 – 2032-05-01 · Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer
What this study did
NCT07933419 · Qilu Pharmaceutical Co., Ltd.
2026-11-15 – 2029-11-15 · Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Other Advanced Solid Tumors
What this study did
NCT07453394 · Qilu Pharmaceutical Co., Ltd.
2026-04 – 2029-02 · Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer
What this study did
NCT02571725 · New Mexico Cancer Research Alliance
2016-02-23 – 2027-07-15 · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms
What this study did
NCT01650376 · Swedish Medical Center
2012-08 – 2019-12 · Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Uterine Cancer
What this study did
Prostate Cancer
NCT03317392 · National Cancer Institute (NCI)
2019-02-04 – 2027-02-16 · Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT02769962 · National Cancer Institute (NCI)
2016-05-09 – 2025-03-04 · Urothelial Carcinoma, Urothelial Cancer, Lung Neoplasms, Small Cell Lung Cancer, Prostate Cancer
What this study did
Other / comorbidity
NCT07850973 · M.D. Anderson Cancer Center
2027-03-01 – 2031-12-31 · Germ Cell Cancer
What this study did
NCT02813135 · Gustave Roussy, Cancer Campus, Grand Paris
2016-08-03 – 2031-02 · Pediatric Cancer
What this study did
NCT06607692 · Fundación de investigación HM
2024-09-20 – 2029-12 · Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumours (NET), Adrenal Tumours, DIPG, Glioblastoma, Glioblastoma (GBM), Osteosarcoma Recurrent, Carcinoma Adrenal, Synovial Sarcomas, Esthesioneuroblastoma, Neuroblastoma Recurrent, Solid Tumor Refractory to Conventional Treatment, Medulloblastoma Recurrent, Paraganglioma/ Phaeochromocytoma, Ependymoma, Ependymoma Recurrent
What this study did
NCT06217757 · Sichuan University
2024-04-18 – 2028-10-31 · Lung Cancer, Extensive-stage Small-cell Lung Cancer
What this study did
NCT05898399 · Artios Pharma Ltd
2023-06-30 – 2028-09-30 · Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT04086485 · National Cancer Institute (NCI)
2022-10-03 – 2028-01-01 · Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine Neoplasms
What this study did
NCT04728230 · M.D. Anderson Cancer Center
2021-01-05 – 2027-12-31 · Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
What this study did
NCT03085147 · Memorial Sloan Kettering Cancer Center
2017-03-15 – 2027-07 · Oral Squamous Cell Carcinoma (OSCC)
What this study did
NCT03212742 · Centre Francois Baclesse
2017-09-04 – 2026-12-31 · Malignant Gliomas, Radiotherapy, PARP Inhibitor
What this study did
NCT02734004 · AstraZeneca
2016-03-17 – 2026-09-17 · Ovarian, Breast, SCLC, Gastric Cancers
What this study did
NCT04592211 · Yonsei University
2021-10-01 – 2026-05-31 · Gastric Cancer Stage IV
What this study did
NCT03008278 · National Cancer Institute (NCI)
2018-02-06 – 2025-08-13 · Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Esophageal Carcinoma, Recurrent Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer AJCC v7, Stage III Gastric Cancer AJCC v7, Stage IV Esophageal Cancer AJCC v7, Stage IV Gastric Cancer AJCC v7, Unresectable Esophageal Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma
What this study did
NCT05405309 · University of Utah
2022-09-23 – 2025-01-10 · Chronic Lymphocytic Leukemia
What this study did
NCT04972110 · Repare Therapeutics
2021-07-21 – 2024-11-13 · Advanced Solid Tumor, Adult
What this study did
NCT03782818 · Laval University
2019-11-20 – 2024-10-31 · Pulmonary Arterial Hypertension
What this study did
NCT05975944 · Tianjin Medical University Cancer Institute and Hospital
2023-09 – 2024-05 · Extensive-stage Small Cell Lung Cancer
What this study did
NCT02446704 · Zofia Piotrowska
2015-10-13 – 2023-12 · Small Cell Lung Cancer
What this study did
NCT04410887 · Ruijin Hospital
2020-12 – 2022-03 · Stomach Cancer, Gastric Cancer
What this study did
NCT02755844 · Hospices Civils de Lyon
2016-09-23 – 2020-06 · Recurrent Endometrial Cancer
What this study did
NCT01513174 · Spanish Lung Cancer Group
2011-08 – 2016-07 · Non Small Cell Lung Cancer
What this study did
Phase 1 (114)
Breast Cancer
NCT07652242 · Immunomic Therapeutics, Inc.
2026-07-14 – 2028-08 · Triple Negative Breast Cancer (TNBC)
What this study did
NCT02208375 · M.D. Anderson Cancer Center
2014-11-11 – 2028-06-30 · BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Endometrial Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, High Grade Ovarian Serous Adenocarcinoma, Progesterone Receptor Negative, Recurrent Breast Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Uterine Corpus Carcinoma, Stage III Uterine Corpus Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Uterine Corpus Cancer AJCC v7, Triple-Negative Breast Carcinoma
What this study did
NCT02898207 · National Cancer Institute (NCI)
2017-05-19 – 2022-01-14 · Metastatic High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Primary Peritoneal Serous Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Breast Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Fallopian Tube Serous Adenocarcinoma, Refractory Ovarian Serous Adenocarcinoma, Refractory Primary Peritoneal Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable High Grade Fallopian Tube Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Primary Peritoneal Serous Adenocarcinoma
What this study did
NCT03109080 · Institut Curie
2017-07-24 – 2021-11-29 · Breast Neoplasms, Triple-Negative, Breast Neoplasm Malignant Female, Radiotherapy Side Effect
What this study did
NCT03544125 · OHSU Knight Cancer Institute
2018-05-03 – 2020-11-18 · Anatomic Stage IV Breast Cancer AJCC v8, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Prognostic Stage IV Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma
What this study did
NCT02227082 · The Netherlands Cancer Institute
2013-10-21 – 2020-08 · Locally Advanced Malignant Neoplasm, Inflammatory Breast Carcinoma, Triple-Negative Invasive Breast Carcinoma
What this study did
NCT00707707 · AstraZeneca
2008-09-15 – 2018-02-19 · Breast Cancer, Triple Negative Breast Cancer, Metastatic Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06856499 · University of Colorado, Denver
2025-12-08 – 2030-09-01 · Endometrioid Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
NCT06488378 · Dana-Farber Cancer Institute
2024-08-13 – 2029-03-01 · Breast Cancer, PALB2-Mutated Breast Carcinoma, HER2-negative Breast Cancer, BRCA1 Mutation, BRCA2 Mutation
What this study did
NCT07156253 · Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd
2025-08-26 – 2029-02-25 · Metastatic Solid Tumor, Ovarian Cancer, Breast Cancer, BRCA 1 /2 and / or HRD, Advanced Solid Tumors
What this study did
NCT05900895 · Mary D Chamberlin
2024-07-15 – 2028-12 · Metastatic Breast Cancer
What this study did
NCT03162627 · M.D. Anderson Cancer Center
2017-08-04 – 2028-08-30 · Malignant Neoplasm of Breast, Malignant Neoplasms of Digestive Organs, Malignant Neoplasms of Female Genital Organs, Malignant Neoplasms of Male Genital Organs, Malignant Neoplasms of Thyroid and Other Endocrine Glands
What this study did
NCT06545942 · MOMA Therapeutics
2024-08-13 – 2027-11-30 · Advanced Solid Tumor, Metastatic Solid Tumor, Prostate Cancer, Pancreas Cancer, Breast Cancer, Ovarian Cancer, Homologous Recombination Deficiency
What this study did
NCT05807126 · National Cancer Institute (NCI)
2024-03-05 – 2026-12-06 · Anatomic Stage IV Breast Cancer AJCC v8, Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8
What this study did
NCT03742245 · The Methodist Hospital Research Institute
2019-06-11 – 2026-12-01 · Breast Cancer Metastatic, Breast Cancer
What this study did
NCT03641755 · Dana-Farber Cancer Institute
2018-10-01 – 2026-10-22 · Breast Cancer
What this study did
NCT05238831 · OHSU Knight Cancer Institute
2023-01-30 – 2026-05-31 · Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Ovarian Carcinoma, Advanced Pancreatic Carcinoma, Advanced Prostate Carcinoma, Advanced Sarcoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Prostate Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
What this study did
NCT03685331 · Abramson Cancer Center at Penn Medicine
2020-10-15 – 2025-12-01 · Metastatic Breast Cancer, Locally Advanced Breast Cancer, Advanced Breast Cancer, BRCA2 Mutation, BRCA1 Mutation
What this study did
NCT04586335 · Haihe Biopharma Co., Ltd.
2020-09-28 – 2023-02-15 · Ovarian Cancer, Breast Cancer, Solid Tumor, Prostate Cancer, Endometrial Cancer
What this study did
NCT03955640 · Thomas Jefferson University
2019-05-20 – 2021-08-26 · Metastatic Malignant Neoplasm in the Chest Wall, Recurrent Breast Carcinoma
What this study did
NCT04041128 · University of Texas Southwestern Medical Center
2019-07-23 – 2021-06-15 · Ovarian Cancer, Breast Cancer
What this study did
NCT03205176 · AstraZeneca
2017-06-30 – 2021-04-08 · Malignant Solid Tumors, Lymphoma, Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer
What this study did
NCT03878524 · OHSU Knight Cancer Institute
2020-04-01 – 2020-12-10 · Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT01237067 · National Cancer Institute (NCI)
2011-02-07 – 2019-12-12 · Ovarian Cancer, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer
What this study did
NCT02418624 · The Netherlands Cancer Institute
2015-05 – 2019-01 · Breast Cancer, Ovarian Cancer, Advanced Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
NCT07090369 · Peter MacCallum Cancer Centre, Australia
2025-11-01 – 2028-12-01 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)
What this study did
NCT03874884 · Peter MacCallum Cancer Centre, Australia
2019-07-09 – 2026-06 · Metastatic Castration Resistant Prostate Cancer (mCRPC)
What this study did
Ovarian Cancer
NCT06976892 · Institute of Cancer Research, United Kingdom
2025-08 – 2029-12 · High Grade Serous Ovarian Cancer
What this study did
NCT03943173 · M.D. Anderson Cancer Center
2019-06-07 – 2027-06-27 · BRCA-Mutated Ovarian Carcinoma, BRCA1 Gene Mutation, BRCA2 Gene Mutation, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IIIA Fallopian Tube Cancer AJCC v8, Stage IIIA Ovarian Cancer AJCC v8, Stage IIIA Primary Peritoneal Cancer AJCC v8, Stage IIIA1 Fallopian Tube Cancer AJCC v8, Stage IIIA1 Ovarian Cancer AJCC v8, Stage IIIA2 Fallopian Tube Cancer AJCC v8, Stage IIIA2 Ovarian Cancer AJCC v8, Stage IIIB Fallopian Tube Cancer AJCC v8, Stage IIIB Ovarian Cancer AJCC v8, Stage IIIB Primary Peritoneal Cancer AJCC v8, Stage IIIC Fallopian Tube Cancer AJCC v8, Stage IIIC Ovarian Cancer AJCC v8, Stage IIIC Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8
What this study did
NCT04633239 · National Cancer Institute (NCI)
2021-07-02 – 2027-05-01 · Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma
What this study did
NCT07371104 · Daewoong Pharmaceutical Co. LTD.
2026-04-22 – 2027-03 · Cancer, Ovarian Cancer
What this study did
NCT04585958 · National Cancer Institute (NCI)
2021-05-21 – 2026-12-31 · Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT02264678 · AstraZeneca
2014-10-31 – 2026-12-30 · Adv Solid Malig - H&N SCC, ATM Pro / Def NSCLC, Gastric, Breast and Ovarian Cancer
What this study did
NCT05358639 · Sunnybrook Health Sciences Centre
2022-11-09 – 2025-04-28 · High Grade Serous Carcinoma, Triple Negative Breast Cancer, Ovarian Cancer
What this study did
NCT00516724 · AstraZeneca
2007-06-22 – 2024-04-11 · Triple Negative Metastatic Breast Cancer, Advanced Ovarian Cancer, Carboplatin, Paclitaxel
What this study did
NCT03378297 · Haukeland University Hospital
2018-05-04 – 2023-01-05 · Ovarian Cancer
What this study did
NCT02855697 · The Christie NHS Foundation Trust
2017-05-26 – 2021-12-31 · Ovarian Cancer
What this study did
NCT02121990 · Memorial Sloan Kettering Cancer Center
2014-04-21 – 2020-08-19 · Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
What this study did
Pancreatic Cancer
NCT05411094 · National Cancer Institute (NCI)
2023-05-22 – 2028-07-01 · Locally Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Unresectable Pancreatic Carcinoma
What this study did
NCT04005690 · OHSU Knight Cancer Institute
2019-08-01 – 2028-02-01 · Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT05252390 · Nuvation Bio Inc.
2022-03-29 – 2024-07-15 · Advanced Solid Tumor, Ovarian Cancer, Ovary Cancer, Cancer of Ovary, Cancer of the Ovary, Ovary Neoplasm, Pancreatic Cancer, Pancreas Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Neoplasm, Prostate Cancer, Prostatic Cancer, Cancer of Prostate, Cancer of the Prostate, Prostate Neoplasm, Castrate Resistant Prostate Cancer, Castration Resistant Prostatic Cancer, Castration Resistant Prostatic Neoplasms, Triple-negative Breast Cancer, Triple Negative Breast Cancer, Triple Negative Breast Neoplasms, Breast Cancer, Breast Carcinoma, Cancer of Breast, Cancer of the Breast, Breast Tumor
What this study did
NCT01296763 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2011-01 – 2016-02 · Pancreatic Cancer
What this study did
NCT00515866 · AstraZeneca
2007-08 – 2012-07 · Pancreatic Neoplasms
What this study did
Prostate Cancer
NCT02324998 · Cambridge University Hospitals NHS Foundation Trust
2016-12 – 2019-05 · Prostate Cancer
What this study did
Other / comorbidity
NCT07382544 · M.D. Anderson Cancer Center
2026-02-12 – 2032-01-31 · Advanced Cancer, Solid Tumor
What this study did
NCT06686745 · Jiangsu Simcere Pharmaceutical Co., Ltd.
2024-12-06 – 2028-12-30 · Advanced Solid Tumors
What this study did
Phase 4 (7)
Breast Cancer
NCT07695259 · Wen-Ming Cao
2026-05-25 – 2027-12-31 · Elderly Females, HER2 + Breast Cancer, Neoadjuvant Therapy
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT05949424 · University Medical Center Groningen
2024-05 – 2025-03 · Renal Cell Carcinoma, Ovarian Carcinoma, Thyroid Carcinoma, Breast Carcinoma, Endometrium Carcinoma
What this study did
NCT04330040 · AstraZeneca
2020-05-25 – 2022-09-30 · Ovarian Cancer, Breast Cancer
What this study did
Metastatic Castration-Resistant Prostate Cancer
Ovarian Cancer
NCT02476968 · AstraZeneca
2015-09-28 – 2021-12-17 · BRCA or HRR+ Mutated Ovarian Cancer Patients
What this study did
Other / comorbidity
NCT06121401 · Mario Negri Institute for Pharmacological Research
2023-09-15 – 2027-09-15 · Carcinoma, Ovarian Epithelial
What this study did
NCT05078671 · Radboud University Medical Center
2021-12-15 – 2025-12-31 · Cancer
What this study did
Early phase / not applicable (4)
Breast Cancer
NCT07187674 · Harbin Medical University
2025-12-30 – 2028-12-31 · Triple Negative Breast Cancer (TNBC)
What this study did
Ovarian Cancer
NCT02681237 · University Health Network, Toronto
2016-04-29 – 2022-03-25 · Ovarian Cancer
What this study did
Other / comorbidity
NCT04801966 · Peter MacCallum Cancer Centre, Australia
2021-09-23 – 2022-12-30 · Cancer
What this study did
NCT05860530 · Qilu Pharmaceutical Co., Ltd.
2021-05-10 – 2021-09-08 · Neoplasms
What this study did
Used as active comparator (1)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Breast Cancer
NCT07486687 · The Netherlands Cancer Institute
2026-04 – 2036-04 · Triple Negative Breast Cancer (TNBC), Early Setting, Early Stage Triple-Negative Breast Carcinoma, Triple -Negative Breast Cancer, Breast Cancer Stage II, Breast Cancer Stage III
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Ovarian Cancer
NCT03278717 · University College, London
2018-06-15 – 2023-12 · Ovarian Cancer
What this study did
Phase 2 (5)
HR+/HER2- Metastatic Breast Cancer
NCT05967286 · National Cancer Institute (NCI)
2023-10-23 – 2025-04-30 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Negative Breast Carcinoma, Unresectable HER2-Negative Breast Carcinoma
What this study did
Pancreatic Cancer
NCT04548752 · National Cancer Institute (NCI)
2021-02-22 – 2027-10-05 · Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer AJCC v8
What this study did
Prostate Cancer
NCT02893917 · National Cancer Institute (NCI)
2017-08-11 – 2027-05-31 · Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma With Neuroendocrine Differentiation, Stage IV Prostate Adenocarcinoma AJCC v7
What this study did
Other / comorbidity
NCT04034927 · National Cancer Institute (NCI)
2019-12-04 – 2027-02-21 · Fallopian Tube Endometrioid Tumor, Fallopian Tube High Grade Serous Adenocarcinoma, Malignant Ovarian Endometrioid Tumor, Ovarian High Grade Serous Adenocarcinoma, Platinum-Sensitive Fallopian Tube Carcinoma, Platinum-Sensitive Ovarian Carcinoma, Platinum-Sensitive Primary Peritoneal Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma
What this study did
NCT05222971 · Asan Medical Center
2022-04-01 – 2026-12-30 · Biliary Tract Cancer, DNA Damage Repair Deficiency
What this study did
Phase 1/2 (1)
Breast Cancer
NCT01116648 · National Cancer Institute (NCI)
2010-04-14 – 2027-06-01 · Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian High Grade Serous Adenocarcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Triple-Negative Breast Carcinoma
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for HR+/HER2- Metastatic Breast Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Olaparib: this drugApprovedSmall moleculePARPPartial signal
NCT02000622: Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1) (Radiological scans performed at baseline then every ~6 weeks up to 24 weeks, then every ~ 12 weeks thereafter until objective radiological disease progression. Assessed up to a maximum of 30 months.): Olaparib 300 mg bd 7 Months (95% CI 5.7 to 8.3) vs Chemotherapy 4.2 Months (95% CI 2.8 to 4.3)
NCT03286842: Progression-free Survival (PFS) in Real-world Setting in Germline BRCA Mutated Participants (At every visit until the earliest of disease progression, death or end of study (up to 3 years)): Olaparib gBRCAm Cohort 8.18 months (95% CI 6.97 to 9.17)
Abemaciclib (Verzenio)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02107703: Progression-Free Survival (PFS) (From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 31 Months)): Abemaciclib + Fulvestrant 16.4 Months (95% CI 14.4 to 19.3) vs Placebo + Fulvestrant 9.3 Months (95% CI 7.4 to 11.4)
NCT02102490: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) (From Date of First Dose until Disease Progression or Death Due to Any Cause (Up To 14 Months)): Abemaciclib 19.7% (95% CI 13.3 to 27.5)
Alpelisib (BYL719)ApprovedSmall moleculePI3K-alphaReliable signal
NCT02437318: Progression-free Survival (PFS) Per Investigator Assessment in the PIK3CA Mutant Cohort (Once approximately 243 PFS events in the PIK3CA mutant cohort had been observed, up to 33.3 months): PIK3CA Mutant Cohort by Tumor Tissue: Alpelisib + Fulvestrant 11 Months (95% CI 7.49 to 14.52) vs PIK3CA Mutant Cohort by Tumor Tissue: Placebo + Fulvestrant 5.7 Months (95% CI 3.65 to 7.36)
AnastrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00291759: Recurrence-free survival, 2yr tamoxifen then 3yr anastrozole vs 5yr tamoxifen: HR 0.80 (95% CI 0.63-1.01), P=.06 (not statistically significant) missed phase 3 result · pivotal pending
NCT00300508: At a median follow-up of 62.3 months, women who received anastrozole (n=387) had a statistically significantly reduced risk of recurrence (locoregional recurrence, contralateral breast cancer or distant metastasis) versus women who received no further treatment (n=469): hazard ratio 0.62 (95% CI 0.40-0.96), P=.031. phase 3 result · pivotal pending
Camizestrant (Etcamah)ApprovedSmall moleculeEstrogen receptorReliable signal
NCT04964934: SERENA-6 (NCT04964934), primary endpoint PFS: median PFS 16.0 months (camizestrant + CDK4/6i) vs 9.2 months (aromatase inhibitor + CDK4/6i); HR 0.44 (95% CI 0.31-0.60); p<0.00001
NCT04588298: Percentage Change From Baseline in Estrogen Receptor (ER) Expression Between Pre- and On-treatment Tumour Samples (Primary Analysis) (Baseline (Screening Day -21 to 1) to Biopsy day (Days 5-7 [Stage 1 and 2] or Days 12-15 [Stage 3])): AZD9833 75 mg (Stage 1 + 2) -62.7% (95% CI -67.46--57.93) vs AZD9833 150 mg (Stage 1 + 2) -62.8% (95% CI -67.13--58.43) vs AZD9833 300 mg (Stage 2) -67.1% (95% CI -74.49--59.74) vs AZD9833 75 mg (Stage 3) -66.9% (95% CI -72.34--61.46) vs AZD9833 150 mg (Stage 3) -65.0% (95% CI -70.27--59.81)
Capecitabine
ApprovedUS marketing discontinued
Small moleculeFluoropyrimidine (antimetabolite)not yet gradedNo reviewed efficacy summary in this indication
CapivasertibApprovedSmall moleculeAKT (inhibitor)Reliable signal
NCT04305496: Progression Free Survival: Overall Population (Months) in the Global Cohort (Assessed every 8 weeks for the first 18 months and every 12 weeks thereafter, from randomization to radiological progression.): Capivasertib + Fulvestrant (Global + China Cohort) 7.2 Months (95% CI 5.5 to 7.4) vs Placebo + Fulvestrant (Global + China Cohort) 3.6 Months (95% CI 2.8 to 3.7)
NCT01625286: Progression-free survival, Part B (randomized vs placebo + paclitaxel): median 10.9 months (95% CI 8.3 to 12.4) with capivasertib vs 8.4 months (95% CI 8.2 to 10.8) with placebo; HR 0.80 (95% CI 0.60 to 1.06), p=0.308 (CT.gov posted results). missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT05104866: Progression-Free Survival (On-study tumor assessments occur every 6 weeks then every 9 weeks until disease progression, death or withdrawal of consent assessed up to data cut-off (17Jul2023) to a maximum of approximately 21 months): Dato-DXd 6.9 Months (95% CI 5.7 to 7.4) vs Investigator's Choice of Chemotherapy (ICC) 4.9 Months (95% CI 4.2 to 5.5)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)Partial signal
NCT00002662: ORR (the registered first objective) 32% vs 25% (P=.10); OS 15.4 vs 12.7 months (P=.03) and TTP 5.7 vs 3.6 months (P<.0001) favored docetaxel. missed
ElacestrantApprovedSmall moleculeEstrogen receptorPartial signal
NCT03778931: Progression-free Survival in ESR1-mut Participants (From Date of Randomization until Disease Progression or Death Due to Any Cause (up to 12 Months)): Elacestrant 3.78 months (95% CI 2.17 to 7.26) vs Standard of Care (SoC) 1.87 months (95% CI 1.87 to 2.14)
Eribulin MesylateApprovedSmall moleculeTubulin / microtubulesPartial signal
NCT02225470: Progression-Free Survival, eribulin vs vinorelbine (independent tumor assessment): HR 0.80 (95% CI 0.65-0.98, P=0.036) in favor of eribulin; median PFS 2.8 months in both arms
NCT00337103: Co-primary endpoints, eribulin (n=554) vs capecitabine (n=548): overall survival median 15.9 vs 14.5 months, HR 0.88 (95% CI 0.77 to 1.00), P = .056; progression-free survival median 4.1 vs 4.2 months, HR 1.08 (95% CI 0.93 to 1.25), P = .30 (Kaufman et al., J Clin Oncol 2015). missed
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Weak signal
NCT02511639: Median progression-free survival: 9.9 months (everolimus + aromatase inhibitor) vs 7.2 months (aromatase inhibitor alone); HR 0.764 (95% CI 0.501-1.164)
NCT00863655: Progression-free Survival (PFS) Based on Local Radiology Review of Tumor Assessments. (date of randomization to the date of first documented tumor progression or death from any cause, whichever occurs first, reported between day of first patient randomized up to about 19 months): Everolimus + Exemestane 6.93 months (95% CI 6.44 to 8.05) vs Placebo + Exemestane 2.83 months (95% CI 2.76 to 4.14)
ExemestaneApprovedSmall moleculeAromatasePartial signal
NCT00002777: Objective response rate: 46% exemestane vs 31% tamoxifen (odds ratio 1.85, 95% CI 1.21-2.82, P=.005). Median progression-free survival (the trial's primary endpoint): 9.9 months exemestane vs 5.8 months tamoxifen; long-term log-rank P=.121 (not statistically significant). missed
Fulvestrant (Faslodex)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT01602380: Comparison of Progression-Free Survival (PFS) in Patients Treated With Fulvestrant With Those Treated With Anastrozole (Baseline RECIST 1.1 assessments (Day 0) and then every 12 weeks until the earliest of disease progression evident, patient dies or has surgery/radiotherapy for their disease (up to approximately 38 months)): Fulvestrant 500 mg 16.6 Months (95% CI 13.83 to 20.99) vs Anastrozole 1 mg 13.8 Months (95% CI 11.99 to 16.59)
NCT00099437: Progression-free survival: fulvestrant 500 mg (n=362) vs 250 mg (n=374), HR 0.80 (95% CI 0.68 to 0.94), P = .006; CT.gov median time to progression 6.5 vs 5.5 months (Di Leo et al., J Clin Oncol 2010).
Gedatolisib (Revtorpyk)ApprovedSmall moleculePI3K (class I isoforms) and mTORC1/mTORC2Partial signal
NCT05501886: VIKTORIA-1 (NCT05501886), PIK3CA wild-type cohort, primary endpoint PFS: gedatolisib+fulvestrant+palbociclib (triplet) median PFS 9.3 months vs fulvestrant alone 2.0 months, HR 0.24 (95% CI 0.17-0.35), p<0.0001; gedatolisib+fulvestrant (doublet) median PFS 7.4 months, HR 0.33 (95% CI 0.24-0.48), p<0.0001.
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Weak signal
NCT00128310: Median progression-free survival: 6.0 months (gemcitabine + vinorelbine) vs 4.0 months (vinorelbine alone); hazard ratio 0.66 (p=0.0028). Overall survival not significantly different (15.9 vs 16.4 months, p=0.8046)
NCT00006459: Eli Lilly's pivotal phase III global registration trial of gemcitabine + paclitaxel vs paclitaxel alone in anthracycline-pretreated advanced breast cancer, matching this listing's title/sponsor. Primary endpoint (overall survival): 18.6 vs 15.8 months, HR 0.78 (95% CI 0.64-0.96), p=0.0187, favoring the gemcitabine combination.
GoserelinApprovedPeptideGnRH receptor (agonist)not yet gradedNo reviewed efficacy summary in this indication
Imlunestrant (Inluriyo)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT04975308: Investigator-assessed PFS. ESR1-mutated population: imlunestrant 5.49 vs 3.84 months with standard endocrine therapy, HR 0.617 (95% CI 0.464 to 0.821), p=0.0008. All patients: 5.55 vs 5.52 months, HR 0.867 (95% CI 0.724 to 1.039), p=0.1158 (not significant). Imlunestrant plus abemaciclib vs imlunestrant: 9.36 vs 5.49 months, HR 0.569 (95% CI 0.441 to 0.733), p<0.0001
Inavolisib (Itovebi)ApprovedSmall moleculePI3K-alphaReliable signal
NCT04191499: Progression-Free Survival (PFS) (Up to 3.7 years): Inavo+Palbo+Fulv 15 months (95% CI 11.3 to 20.5) vs Pbo+Palbo+Fulv 7.3 months (95% CI 5.6 to 9.3)
IxabepiloneApprovedSmall moleculeMicrotubules (tubulin)Partial signalFeatured results are non-efficacy only in this race
LetrozoleApprovedSmall moleculeAromatasenot yet graded
NCT00003140: Estimated 4-year disease-free survival: letrozole 93% vs placebo 87% (75 vs 132 recurrences/new cancers out of 5187 enrolled); P<=0.001 phase 3 result · pivotal pending
NCT00004205: Disease-free survival (primary endpoint), letrozole vs tamoxifen: 5-year DFS 84.0% vs 81.4%; HR 0.81 (95% CI 0.70-0.93), P=0.003, at median follow-up 25.8 months (351 vs 428 events; N=8010). phase 3 result · pivotal pending
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00785291: Progression Free Survival (Time from randomization to progression or death due to any cause, whichever occurs first (up to 5 years)): Arm B (Nab-paclitaxel) 9.3 months (95% CI 8.15 to 10.45) vs Arm A (Paclitaxel) 10.97 months (95% CI 9.79 to 12.42) vs Arm C (Ixabepilone) 7.36 months (95% CI 6.21 to 8.18) missed
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02297438: Progression-Free Survival (PFS) Based on Investigator's Assessment: Up to Primary Completion Date (Randomization up to 65 months): Palbociclib + Letrozole 21.5 Months (95% CI 16.6 to 24.9) vs Placebo + Letrozole 13.9 Months (95% CI 13.7 to 16.6)
NCT01740427: Progression-Free Survival (PFS) as Assessed by the Investigator (From randomization date to date of first documentation of progression or death (up to approximately 2.5 years)): Palbociclib Plus Letrozole 24.8 Months vs Placebo Plus Letrozole 14.5 Months (95% CI 12.9 to 17.1)
RibociclibApprovedSmall moleculeCDK4 and CDK6Reliable signal
NCT02422615: Progression Free Survival (PFS) Per Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 26 months): Ribociclib + Fulvestrant 20.5 Months (95% CI 18.5 to 23.5) vs Placebo + Fulvestrant 12.8 Months (95% CI 10.9 to 16.3)
NCT02278120: Progression Free Survival (PFS) by Investigator Assessment (From randomization to first documented progression or death, assessed up to approximately 29 months): Ribociclib + NSAI/Tamoxifen + Goserelin 23.8 Months vs Placebo + NSAI/Tamoxifen+ Goserelin 13 Months (95% CI 11 to 16.4)
Sacituzumab GovitecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT03901339: Progression-Free Survival (PFS) by Blinded Independent Central Review (BICR) Assessment (Up to 42.8 months): Sacituzumab Govitecan 5.5 months (95% CI 4.2 to 6.9) vs Treatment of Physician's Choice (TPC) 4 months (95% CI 3 to 4.4)
TalazoparibApprovedSmall moleculePARPPartial signal
NCT01945775: Progression-Free Survival (PFS): Independent Radiological Facility (IRF) Assessment (Baseline until radiologic progressive disease or death due to any cause (up to maximum duration of 36.9 months)): Talazoparib 8.6 months (95% CI 7.2 to 9.3) vs Physician's Choice Treatment 5.6 months (95% CI 4.2 to 6.7)
Tamoxifen (Soltamox)ApprovedSmall moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9)
NCT03734029: Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer (From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years): Trastuzumab Deruxtecan (T-DXd) 10.1 months (95% CI 9.5 to 11.5) | Physician's Choice 5.4 months (95% CI 4.4 to 7.1)
Vepdegestrant (Veppanu)ApprovedSmall moleculeEstrogen receptorPartial signal
NCT05654623: PFS by BICR vs fulvestrant: ESR1-mutation population median 5.0 vs 2.1 months, hazard ratio 0.58 (95% CI 0.43 to 0.78), P<0.001; all randomized patients 3.8 vs 3.6 months, hazard ratio 0.83 (95% CI 0.69 to 1.01), P=0.07 (NEJM 2025).
NCT04072952: Clinical benefit rate 38% (total n=71), the trial's primary endpoint (VERITAC expansion); CBR 51.2% in ESR1-mutant patients (n=41)
AfuresertibPhase 3Small moleculeAKT (inhibitor)Partial signal
NCT04851613: Primary endpoint, progression-free survival: median 7.6 months with afuresertib plus fulvestrant vs 2.0 months with placebo plus fulvestrant (sponsor topline, 2026-04-15).
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
AtirmociclibPhase 3Small moleculeCDK4Partial signal
NCT06465368: Percentage of Participants With Complete Cell Cycle Arrest (CCCA) at Day 14 (Day 14): PF-07220060 + Letrozole 88.2% (95% CI 76.6-94.5) vs Letrozole Alone 17.9% (95% CI 10.0-29.8)
BEBT-209Phase 3Small moleculeCDK4 (selective)not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
BGB-43395Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
BireociclibPhase 3Small moleculeCDK2/4/6Reliable signal
NCT05077449: BRIGHT-2 (NCT05077449), primary endpoint median PFS: bireociclib (XZP-3287) + fulvestrant 14.7 months vs placebo + fulvestrant 7.3 months; HR 0.54 (95% CI 0.40-0.74); p<0.001
ChidamidePhase 3Small moleculeHDACReliable signal
NCT02482753: Investigator-assessed median PFS: 7.4 months (95% CI 5.5-9.2) chidamide+exemestane vs 3.8 months (95% CI 3.7-5.5) placebo+exemestane; hazard ratio 0.755, p=0.0336
CulmerciclibPhase 3Small moleculeCDK2/CDK4/CDK6, CDK2/4/6/CDK4Partial signal
NCT05375461: Median investigator-assessed PFS: 16.6 months (culmerciclib + fulvestrant) vs 7.5 months (placebo + fulvestrant); HR 0.36 (95% CI 0.26-0.51), P<0.001, meeting the primary endpoint.
DalpiciclibPhase 3Small moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
Denosumab (Xgeva)Phase 3Monoclonal antibodyRANKLnot yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 3Antibody–drug conjugateHER2Partial signal
NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months
GiredestrantPhase 3Small moleculeEstrogen receptorPartial signal
NCT04546009: persevERA (NCT04546009), primary endpoint investigator-assessed PFS: giredestrant plus palbociclib median PFS 33.1 months vs letrozole plus palbociclib 28.2 months; HR 0.89 (95% CI 0.76-1.05); p=.1553. missed
HRS-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
HRS-8080Phase 3Small moleculeEstrogen receptor (degrader)not yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
JS105Phase 3Small moleculePI3K-alpha (mutant-selective)not yet gradedNo reviewed efficacy summary in this indication
NTQ1062Phase 3Small moleculeAKT (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
PalazestrantPhase 3Small moleculeEstrogen receptorWeak signalNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signalNo reviewed efficacy summary in this indication
PembrolizumabPhase 3Monoclonal antibodyPD-1Partial signalNo reviewed efficacy summary in this indication
PrifetrastatPhase 3Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2not yet gradedNo reviewed efficacy summary in this indication
SaruparibPhase 3Small moleculePARP1 inhibitor (next-gen)not yet gradedNo reviewed efficacy summary in this indication
SHR-6209Phase 3Small moleculeCDK4not yet gradedNo reviewed efficacy summary in this indication
Sirolimus For Injection (Albumin-Bound)Phase 3Small moleculemTOR (mechanistic target of rapamycin complex 1), via FKBP-12not yet gradedNo reviewed efficacy summary in this indication
TaragarestrantPhase 3Small moleculeEstrogen receptornot yet gradedNo reviewed efficacy summary in this indication
TersolisibPhase 3Small moleculePI3K-alpha (mutant-selective, allosteric)not yet gradedNo reviewed efficacy summary in this indication
Tibremciclib (Kangmeina)Phase 3Small moleculeCDK4 and CDK6Partial signal
NCT05433480: Investigator-assessed PFS: tibremciclib plus fulvestrant median 16.5 months (95% CI 12.8 to 16.6) vs placebo plus fulvestrant 5.6 months (95% CI 4.5 to 9.2); HR 0.37 (95% CI 0.27 to 0.52), P<.001
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesnot yet gradedNo reviewed efficacy summary in this indication
Zoledronic AcidPhase 3Small moleculeFarnesyl pyrophosphate synthase (FPPS)not yet gradedNo reviewed efficacy summary in this indication
(Z)-EndoxifenPhase 2Small moleculeEstrogen receptor (antagonist)not yet gradedNo reviewed efficacy summary in this indication
ECI830Phase 1/2Small moleculeCDK2not yet gradedNo reviewed efficacy summary in this indication
GVV858Phase 1/2—CDK2not yet gradedNo reviewed efficacy summary in this indication
MRT-2359Phase 1/2Small moleculeGSPT1not yet gradedNo reviewed efficacy summary in this indication
RezatapoptPhase 1/2Small moleculep53 reactivatornot yet gradedNo reviewed efficacy summary in this indication
Rinatabart Sesutecan (Rina-S)Phase 1/2Antibody–drug conjugateFolate receptor alpha (FRα)not yet gradedNo reviewed efficacy summary in this indication
IEV407Phase 1——not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 68 furthest-along competitors are listed; 37 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(104 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Olaparib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (9)
November 2026 (1)
Phase 2Pancreatic CancerActive not recruiting
Est. primary completion 2026-11-30 · NCT05093231 · CT.gov ↗
What to watch
December 2026 (8)
Phase 2Breast CancerRecruiting
Est. primary completion 2026-12 · NCT03740893 · CT.gov ↗
What to watch
Phase 2Advanced Bladder Carcinoma, Advanced Genitourinary System Carcinoma, Metastatic Bladder Carcinoma …Active not recruiting
Est. primary completion 2026-12-16 · NCT03375307 · CT.gov ↗
What to watch
Phase 1Solid Tumor, AdultRecruiting
Est. primary completion 2026-12-31 · NCT03772561 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2026-12-31 · NCT04585958 · CT.gov ↗
What to watch
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2026-12-31 · NCT03594396 · CT.gov ↗
What to watch
Phase 2Solid Tumor, Precision MedicineRecruiting
Est. primary completion 2026-12-31 · NCT06739395 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2026-12-31 · NCT03297606 · CT.gov ↗
What to watch
Phase 2Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal CarcinomaActive not recruiting
Est. primary completion 2026-12-31 · NCT03579316 · CT.gov ↗
What to watch
2027 (51)
January 2027 (6)
Phase 2Metastatic Pancreatic Ductal Adenocarcinoma, Homologous Recombination Deficiency (HRD)Active not recruiting
Est. primary completion 2027-01 · NCT04666740 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT04683679 · CT.gov ↗
What to watch
Phase 2GliomaRecruiting
Est. primary completion 2027-01 · NCT05188508 · CT.gov ↗
What to watch
Phase 1Neuroendocrine Tumors, Peptide Receptor Radionuclide TherapyRecruiting
Est. primary completion 2027-01-01 · NCT05870423 · CT.gov ↗
What to watch
Phase 2Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, LeiomyosarcomaActive not recruiting
Est. primary completion 2027-01-01 · NCT03851614 · CT.gov ↗
What to watch
Phase 2Squamous Cell Carcinoma of Head and NeckActive not recruiting
Est. primary completion 2027-01-21 · NCT05366166 · CT.gov ↗
What to watch
March 2027 (4)
Phase 1Ovarian CancerRecruiting
Est. primary completion 2027-03 · NCT07371104 · CT.gov ↗
What to watch
Phase 2Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Kidney Cancer, Renal Carcinoma, Kidney Cancer MetastaticRecruiting
Est. primary completion 2027-03 · NCT03786796 · CT.gov ↗
What to watch
Phase 4Carcinoma, Ovarian EpithelialActive not recruiting
Est. primary completion 2027-03-15 · NCT06121401 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-03-30 · NCT07113964 · CT.gov ↗
What to watch
April 2027 (3)
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2027-04 · NCT07453394 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-04-06 · NCT04421963 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2027-04-30 · NCT05932862 · CT.gov ↗
What to watch
May 2027 (7)
Phase 2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-05 · NCT06909825 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-01 · NCT06488378 · CT.gov ↗
What to watch
Phase 1Ovarian CancerRecruiting
Est. primary completion 2027-05-01 · NCT04633239 · CT.gov ↗
What to watch
Phase 1/2Ovarian CancerRecruiting
Est. primary completion 2027-05-01 · NCT07460180 · CT.gov ↗
What to watch
Phase 3Lung Neoplasms, Carcinoma, Non-Small-Cell LungActive not recruiting
Est. primary completion 2027-05-05 · NCT04380636 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-05-30 · NCT07005583 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-05-31 · NCT06545942 · CT.gov ↗
What to watch
June 2027 (4)
Phase 1Pancreatic CancerRecruiting
Est. primary completion 2027-06-01 · NCT04005690 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-06-01 · NCT03598257 · CT.gov ↗
What to watch
Phase 1Ovarian CancerActive not recruiting
Est. primary completion 2027-06-27 · NCT03943173 · CT.gov ↗
What to watch
Phase 1Advanced Solid TumorsRecruiting
Est. primary completion 2027-06-30 · NCT06686745 · CT.gov ↗
What to watch
July 2027 (6)
Phase 1/2Oral Squamous Cell Carcinoma (OSCC)Active not recruiting
Est. primary completion 2027-07 · NCT03085147 · CT.gov ↗
What to watch
Phase 2SCLC,Extensive StageRecruiting
Est. primary completion 2027-07 · NCT05623319 · CT.gov ↗
What to watch
Phase 2Uveal Melanoma, Ocular MelanomaActive not recruiting
Est. primary completion 2027-07 · NCT05524935 · CT.gov ↗
What to watch
Phase 1Glioblastoma, Recurrent Disease, Recurrent GlioblastomaEnrolling by invitation
Est. primary completion 2027-07-01 · NCT05432518 · CT.gov ↗
What to watch
Phase 1/2Gastroenteropancreatico Tumors, Neuroendocrine Tumors, Neuroendocrine NeoplasmsRecruiting
Est. primary completion 2027-07-01 · NCT04086485 · CT.gov ↗
What to watch
Phase 1Solid TumorsActive not recruiting
Est. primary completion 2027-07-27 · NCT05238922 · CT.gov ↗
What to watch
August 2027 (2)
Phase 2ImmunotherapyActive not recruiting
Est. primary completion 2027-08-10 · NCT04169841 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-08-31 · NCT04038502 · CT.gov ↗
What to watch
September 2027 (2)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09 · NCT06298084 · CT.gov ↗
What to watch
Phase 2Cancer, Tumors, Neoplasm, NeoplasiaRecruiting
Est. primary completion 2027-09 · NCT02925234 · CT.gov ↗
What to watch
October 2027 (6)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-10 · NCT06686030 · CT.gov ↗
What to watch
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2027-10-22 · NCT02861573 · CT.gov ↗
What to watch
Phase 3Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-10-28 · NCT04624204 · CT.gov ↗
What to watch
Phase 1/2Colorectal Neoplasms, Breast NeoplasmsActive not recruiting
Est. primary completion 2027-10-30 · NCT02484404 · CT.gov ↗
What to watch
Phase 1/2Lung Cancer, Extensive-stage Small-cell Lung CancerRecruiting
Est. primary completion 2027-10-31 · NCT06217757 · CT.gov ↗
What to watch
Phase 2Pancreatic CancerRecruiting
Est. primary completion 2027-10-31 · NCT04858334 · CT.gov ↗
What to watch
November 2027 (1)
Phase 1/2Ovarian CancerNot yet recruiting
Est. primary completion 2027-11-15 · NCT07933419 · CT.gov ↗
What to watch
December 2027 (10)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12 · NCT05900895 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT07695259 · CT.gov ↗
What to watch
Phase 2Prostate CancerRecruiting
Est. primary completion 2027-12-02 · NCT05568550 · CT.gov ↗
What to watch
Phase 2Renal Cell CancerRecruiting
Est. primary completion 2027-12-30 · NCT03741426 · CT.gov ↗
What to watch
Phase 1/2Extensive Stage Lung Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8Active not recruiting
Est. primary completion 2027-12-31 · NCT04728230 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07407452 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2027-12-31 · NCT02489006 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2027-12-31 · NCT07667751 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT04090567 · CT.gov ↗
What to watch
2028 (23)
January 2028 (6)
Phase 2Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell LymphomaRecruiting
Est. primary completion 2028-01 · NCT06160843 · CT.gov ↗
What to watch
Phase 2Malignant Solid NeoplasmsRecruiting
Est. primary completion 2028-01 · NCT02029001 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-01 · NCT07024784 · CT.gov ↗
What to watch
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-01 · NCT04644289 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-01-21 · NCT05255471 · CT.gov ↗
What to watch
Phase 1BRCA1 Mutation, BRCA2 Mutation, BRCA Mutation, PALB2 Gene Mutation, Checkpoint Kinase 2 Gene Mutation, ATM Gene MutationActive not recruiting
Est. primary completion 2028-01-31 · NCT06177171 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1Breast CancerRecruiting
Est. primary completion 2028-02 · NCT07652242 · CT.gov ↗
What to watch
Phase 2Ovarian CancerActive not recruiting
Est. primary completion 2028-02-28 · NCT04931342 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma …Active not recruiting
Est. primary completion 2028-03-01 · NCT04394858 · CT.gov ↗
What to watch
Phase 2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2028-03-31 · NCT03682289 · CT.gov ↗
What to watch
April 2028 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-04-01 · NCT05128734 · CT.gov ↗
What to watch
Phase 2Mesothelioma, Homologous Recombination DeficiencyRecruiting
Est. primary completion 2028-04-15 · NCT04515836 · CT.gov ↗
What to watch
June 2028 (4)
Early phase / not applicableBreast CancerNot yet recruiting
Est. primary completion 2028-06-15 · NCT07187674 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2028-06-30 · NCT02208375 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2028-06-30 · NCT05898399 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2028-06-30 · NCT05485766 · CT.gov ↗
What to watch
August 2028 (2)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-08-25 · NCT07156253 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2028-08-30 · NCT03162627 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Ovarian CancerRecruiting
Est. primary completion 2028-10-30 · NCT05952453 · CT.gov ↗
What to watch
November 2028 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2028-11-20 · NCT06112379 · CT.gov ↗
What to watch
Phase 3Advanced or Recurrent Endometrial CancerActive not recruiting
Est. primary completion 2028-11-30 · NCT06746116 · CT.gov ↗
What to watch
December 2028 (2)
Phase 2/3Metastatic Castration-Resistant Prostate CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07641855 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06201234 · CT.gov ↗
What to watch
2029 (8)
January 2029 (2)
Phase 1/2Metastatic Castration-Resistant Prostate CancerActive not recruiting
Est. primary completion 2029-01-15 · NCT06353386 · CT.gov ↗
What to watch
Phase 2Ovary Cancer, Peritoneal Cancer, Fallopian Tube CancerRecruiting
Est. primary completion 2029-01-31 · NCT05887609 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-06 · NCT06245889 · CT.gov ↗
What to watch
July 2029 (1)
Phase 1/2Solid Tumor Cancer, Medulloblastoma, High Risk Neuroblastoma, High Grade Gliomas, Meningioma, Paraganglioma, Pheochromocytoma …Recruiting
Est. primary completion 2029-07 · NCT06607692 · CT.gov ↗
What to watch
December 2029 (4)
Phase 1Ovarian CancerRecruiting
Est. primary completion 2029-12 · NCT06976892 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-12-01 · NCT06856499 · CT.gov ↗
What to watch
Phase 1/2Germ Cell CancerNot yet recruiting
Est. primary completion 2029-12-31 · NCT07850973 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2029-12-31 · NCT06797635 · CT.gov ↗
What to watch
2030 (6)
January 2030 (1)
Phase 1Advanced Cancer, Solid TumorRecruiting
Est. primary completion 2030-01-31 · NCT07382544 · CT.gov ↗
What to watch
March 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03 · NCT05332561 · CT.gov ↗
What to watch
June 2030 (1)
Phase 3Endometrial Cancer, p53abnRecruiting
Est. primary completion 2030-06 · NCT06712472 · CT.gov ↗
What to watch
July 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-01 · NCT05564377 · CT.gov ↗
What to watch
September 2030 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2030-09-01 · NCT05522491 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-12 · NCT01042379 · CT.gov ↗
What to watch
2031 (2)
February 2031 (2)
Phase 1/2Pediatric CancerRecruiting
Est. primary completion 2031-02 · NCT02813135 · CT.gov ↗
What to watch
Phase 2Ovarian CancerNot yet recruiting
Est. primary completion 2031-02-28 · NCT07647653 · CT.gov ↗
What to watch
2032 (1)
October 2032 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2032-10-31 · NCT06915025 · CT.gov ↗
What to watch
2033 (2)
January 2033 (1)
Phase 2Biliary Tract Cancer (BTC)Not yet recruiting
Est. primary completion 2033-01 · NCT07938645 · CT.gov ↗
What to watch
March 2033 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2033-03-23 · NCT06966700 · CT.gov ↗
What to watch
2034 (1)
December 2034 (1)
Phase 3Ovarian CancerRecruiting
Est. primary completion 2034-12-31 · NCT06580314 · CT.gov ↗
What to watch
2043 (1)
August 2043 (1)
Phase 3Solid Tumors, Hematologic MalignanciesRecruiting
Est. primary completion 2043-08-04 · NCT03486873 · CT.gov ↗
What to watch

See the full readout calendar ↗